Bone Cancer Market

SKU: DMPH2058 | Last Updated On: Nov 09 2022 | Available Formats

Bone Cancer Market Expected to reach a high CAGR of 8.7% By 2029:

Bone Cancer Market is segmented By Type (Primary bone cancer (Osteosarcoma, Chondrosarcoma, Ewing’s sarcoma Others), Secondary bone cancer), By Treatment (Chemotherapy, Targeted therapy, Radiation therapy Cryosurgery, Others), By End-user (Hospitals, Clinics, Cancer Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

[150 Pages Report] Bone Cancer Market was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 8.7% during the forecast period (2022-2029).      

Endometrial Cancer Market Scope



Market CAGR


Segments Covered

By Type, By Treatment, By End-user, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Bone cancer is due to the formation of a tumor, or abnormal mass of tissue in a bone. Primary bone cancers are the severe type of all bone cancers. They form directly in the bones or the surrounding tissue, like cartilage. The factors like the adoption of metastatic bone cancer treatment by the orthopedics, surgeons, and medical specialties are driving the market.

Market Dynamics

The major driving forces are the rising incidence of bone cancer, growing research and development activities, promising pipeline studies, and increasing government initiatives for bone cancer awareness.

The rising incidences of bone cancer are expected to drive the market growth     

The rising incidences of bone cancer are boosting the market over the forecast period. For instance, according to the National Cancer Institute, primary bone cancer is rare, and it accounts for much less than 1% of all new cancers diagnosed. As per the American Cancer Society’s 2022 estimate about 3,910 new bone cases diagnosed in the USA, resulting in 2,100 deaths. Primary bone cancers (cancers that start in the bones) are uncommon, accounting for less than 1% of all cancers. In adults, cancers that spread to the bones from other organs (known as bone metastasis) are much more common than primary bone cancers.

The presence of government initiatives in the treatment of bone cancer are expected to boost the market. For instance, the European Commission-funded VERDI project developed an innovative multifunctional nanoplatforms which is capable of healing hard-to-treat bone diseases using a unique, versatile, and scalable system. The Stryker partially funded the work with co-funding from the Innovative Manufacturing Cooperative Research Centre (IMCRC), which contributed to $A2.36 million in cash. Thus, the increasing number of government initiatives are driving the market.

The side effects associated with the treatment will hamper the growth of the market  

However, the side effects associated with the treatment are restraining the market. For instance, according to the Cancer Support Community, chemotherapy is often a part of treatment for Ewing sarcoma and osteosarcoma. The side effects include hair loss, mouth sores, loss of appetite, increased chance of infections (owing to low white blood cell counts), bleeding (owing to low blood platelet counts) and fatigue (owing to low red blood cell counts).

Segment Analysis

The primary bone cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The primary bone cancer segment is expected to boost the market, owing to the increased number of incidences leading to growing research activities. For instance, the American Cancer Society has estimated that each year, around 800 to 900 new cases of osteosarcoma are reported in the US. Also, half of these are in children and teens. About 10% of all osteosarcomas occur in people older than 60 age. However, the treatment of osteosarcoma is challenging.

Moreover, most types of cancer can spread to the bone, and bone cancer is particularly likely with specific cancers, including the prostate and breast. Metastatic tumors in the bone can cause pain, fractures, and abnormally high levels of calcium in the blood, a situation called hypercalcemia.

Geographical Analysis

North America region holds the largest market share of the Global Bone Cancer Market

North America dominates the market for insulin pens and is expected to show a similar trend over the forecast period owing to the rising incidences of bone cancer and the rapid research and development of innovative, advanced cancer therapies. As per, in 2021, an estimated 3,910 individuals of all periods (2,160 men and boys and 1,750 women and girls) in the United States will be diagnosed with primary bone sarcoma. In 2020, it was estimated that about 400 of these cases emerged in people aged 15 to 19. Ongoing research and development activities are expected to boost the market. For instance, a Washington State University research team has developed a drug delivery system using curcumin, which successfully inhibits bone cancer cells while promoting the growth of healthy bone cells. Also, the work could lead to better postoperative treatments for people with osteosarcoma. Thus, the presence of research activities is driving the market in the region.

Competitive Landscape

The bone cancer market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market are Amgen, Bayer AG, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., Inc., F. Hoffman-La Roche, and Takeda Pharmaceutical Company among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the bone cancer market globally. For instance, in December 01, 2021, Zetagen Therapeutics, received Breakthrough Device designation from the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its ZetaMet technology. Previously known as ZetaFuse, ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.



Amgen Inc. is a self-dependent biotechnology pharmaceutical company that develops, manufactures, discovers, and markets drugs for deplorable conditions. The Company focuses on human therapeutics and concentrates on innovating novel medicines established in cellular and molecular biology.     

Product Portfolio:

Prolia (Denosumab): Prolia is the first approved therapy that specifically targets RANK Ligand, an essential regulator of bone-removing cells (osteoclasts). Prolia is approved in the U.S. for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The global bone cancer market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.  


Frequently Asked Questions

What is the Projected CAGR value of the Endometrial Cancer Market?

Endometrial Cancer Market is expected to grow at a CAGR of 8.7% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Endometrial Cancer Market during 2022-2029.

Which is the fastest growing region in the Endometrial Cancer Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Bone Cancer Diagnosis Market

Bone and Joint Health Supplements Market

Cancer Treatment Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!